R
Richard Levin
Researcher at Chesapeake Energy
Publications - 14
Citations - 446
Richard Levin is an academic researcher from Chesapeake Energy. The author has contributed to research in topics: Lower urinary tract symptoms & Randomized controlled trial. The author has an hindex of 6, co-authored 14 publications receiving 292 citations. Previous affiliations of Richard Levin include University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Kevin T. McVary,Steven N. Gange,Marc Gittelman,Kenneth Goldberg,Kalpesh Patel,Neal D. Shore,Richard Levin,Michael Rousseau,J. Randolf Beahrs,Jed Kaminetsky,Barrett E. Cowan,Christopher H. Cantrill,Lance A. Mynderse,James Ulchaker,Thayne R. Larson,Christopher M. Dixon,Claus G. Roehrborn +16 more
TL;DR: Convective water vapor thermal therapy provides rapid and durable improvements in benign prostatic hyperplasia symptoms and preserves erectile and ejaculatory function.
Journal ArticleDOI
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study
Kevin T. McVary,Steven N. Gange,Marc Gittelman,Kenneth Goldberg,Kalpesh Patel,Neal D. Shore,Richard Levin,Michael Rousseau,J. Randolf Beahrs,Jed Kaminetsky,Barrett E. Cowan,Christopher H. Cantrill,Lance A. Mynderse,James Ulchaker,Thayne R. Larson,Christopher M. Dixon,Claus G. Roehrborn +16 more
TL;DR: Convective water vapor thermal therapy provides sustainable improvements for 12 months to lower urinary tract symptoms and urinary flow while preserving erectile and ejaculatory functions.
Journal ArticleDOI
Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Claus G. Roehrborn,Steven N. Gange,Marc Gittelman,Kenneth Goldberg,Kalpesh Patel,Neal D. Shore,Richard Levin,Michael Rousseau,J. Randolf Beahrs,Jed C. Kaminetsky,Barrett E. Cowan,Christopher H. Cantrill,Lance A. Mynderse,James Ulchaker,Thayne R. Larson,Christopher M. Dixon,Kevin T. McVary +16 more
TL;DR: Convective radiofrequency water vapor thermal therapy is a minimally invasive office or outpatient procedure that provides early effective symptom relief that remains durable for 2 years and is applicable to the median lobe.
Journal ArticleDOI
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Kevin T. McVary,Marc Gittelman,Kenneth Goldberg,Kalpesh Patel,Neal D. Shore,Richard Levin,Marc J. Pliskin,J. Randolf Beahrs,David Prall,Jed Kaminetsky,Barrett E. Cowan,Christopher H. Cantrill,Lance A. Mynderse,James Ulchaker,Nicholas N. Tadros,Steven N. Gange,Claus G. Roehrborn +16 more
TL;DR: Minimally invasive treatment with Rezum water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical retreatment rates and without impacting sexual function.
Journal ArticleDOI
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Cy A. Stein,Richard Levin,Robert Given,Celestia S. Higano,Paul Nemeth,Bill Bosch,Jillian Chapas-Reed,Robert Dreicer +7 more
TL;DR: Therapeutic equivalence between AAFP 500mg daily and OAA 1000mg daily based on serum testosterone levels was confirmed in mCRPC patients, and both agents led to similar PSA-50 response rates.